Published in Ann Oncol on October 01, 2012
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors | NCT04852965
Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc (2014) 1.01
Role of echocardiography in the management of cardiac disease in women. J Cardiovasc Ultrasound (2014) 0.92
Suicide Gene Therapy for Cancer - Current Strategies. J Genet Syndr Gene Ther (2013) 0.87
Heterogeneity of glycolysis in cancers and therapeutic opportunities. Biochem Pharmacol (2014) 0.86
Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment. Front Oncol (2014) 0.85
Cardiac effects of anticancer therapy in the elderly. J Clin Oncol (2014) 0.84
Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res (2015) 0.84
Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. Ann Pharmacother (2016) 0.83
Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol (2015) 0.83
Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J (2013) 0.83
The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review. BMC Cancer (2015) 0.82
Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. Biomed Res Int (2015) 0.81
Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol (2014) 0.81
Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart (2015) 0.81
Ubiquinol reduces muscle wasting but not fatigue in tumor-bearing mice. Biol Res Nurs (2014) 0.79
Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail (2016) 0.79
Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev (2015) 0.79
The Crossroads of Geriatric Cardiology and Cardio-Oncology. Curr Geriatr Rep (2015) 0.78
Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy. Curr Heart Fail Rep (2015) 0.78
Cardiac risk in the treatment of breast cancer: assessment and management. Breast Cancer (Dove Med Press) (2015) 0.78
More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review. Onco Targets Ther (2014) 0.78
Cardiovascular sequelae of radiation therapy. Clin Res Cardiol (2014) 0.77
The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer (2016) 0.77
Current views on anthracycline cardiotoxicity. Heart Fail Rev (2016) 0.77
AECHL-1, a novel triterpenoid, targets tumor neo-vasculature and impairs the endothelial cell cytoskeleton. Angiogenesis (2015) 0.76
Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure. J Appl Genet (2013) 0.76
Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials. Indian J Pharmacol (2016) 0.75
Characteristics of patients with haematological and breast cancer (1996-2009) who died of heart failure-related causes after cancer therapy. ESC Heart Fail (2016) 0.75
Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Target Oncol (2016) 0.75
Radiotherapy and anthracyclines - cardiovascular toxicity. Contemp Oncol (Pozn) (2014) 0.75
Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy. Clin Med Insights Cardiol (2015) 0.75
Discovering Outliers of Potential Drug Toxicities Using a Large-scale Data-driven Approach. Cancer Inform (2016) 0.75
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. Clin Transl Oncol (2016) 0.75
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy. Biomark Cancer (2016) 0.75
Prediction of years of life after diagnosis of breast cancer using omics and omic-by-treatment interactions. Eur J Hum Genet (2017) 0.75
Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Pract (2017) 0.75
Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference? BBA Clin (2016) 0.75
Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer. PLoS One (2016) 0.75
Trastuzumab cardiotoxicity in patients with breast cancer. Arq Bras Cardiol (2014) 0.75
An International Survey of Health Care Providers Involved in the Management of Cancer Patients Exposed to Cardiotoxic Therapy. J Oncol (2015) 0.75
A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown) (2016) 0.75
Illuminating anthracycline cardiotoxicity: the renaissance of evidence-based onco-cardiology. J Thorac Dis (2015) 0.75
Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. Oncologist (2016) 0.75
Targeting precision medicine toxicity: recent developments. Ther Adv Drug Saf (2015) 0.75
Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines. J Cancer (2014) 0.75
Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin. Oncologist (2017) 0.75
Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open (2016) 0.75
Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance. Biomed Res Int (2016) 0.75
Diagnostic Strategies for Early Recognition of Cancer Therapeutics-Related Cardiac Dysfunction. Clin Med Insights Cardiol (2017) 0.75
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med (2016) 0.75
Acute effects of chemoradiation on cardiac function in oesophageal cancer: a MUGA scan and echo-based study. Heart Asia (2015) 0.75
Cancer and Heart Failure: Understanding the Intersection. Card Fail Rev (2017) 0.75
Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity. Curr Oncol Rep (2017) 0.75
Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc (2017) 0.75
Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts. Curr Oncol Rep (2017) 0.75
Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments. Front Pharmacol (2017) 0.75
The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. Card Fail Rev (2016) 0.75
Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Support Care Cancer (2016) 0.75
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet (2000) 3.79
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet (1999) 3.50
Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood (2001) 3.24
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 3.17
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 3.06
Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 3.03
Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet (2008) 2.91
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 2.80
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 2.77
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.75
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 2.67
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.63
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 2.54
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.53
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.49
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.31
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol (2008) 2.26
Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol (2010) 2.19
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol (2012) 2.09
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.08
Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 2.07
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol (2013) 2.06
Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 2.06
Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol (2001) 2.05
Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol (1998) 2.05
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol (2012) 2.04
Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol (2002) 2.03
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy. Bone Marrow Transplant (2000) 1.95
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 1.93
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92
Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91
Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med (1991) 1.88
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.87
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.84
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol (2000) 1.81
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.79
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet (2001) 1.79
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77
Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol (2003) 1.75
Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol (2002) 1.73
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.73
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.72
Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol (2011) 1.71
Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst (1992) 1.70
Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol (1996) 1.70
Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol (2007) 1.69
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol (2010) 1.69
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.67
Outcome of special types of luminal breast cancer. Ann Oncol (2011) 1.67
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol (2000) 1.66
Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med (1994) 1.66
Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2010) 1.65
Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys (1996) 1.63
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.63
Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 1.61
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.60
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.60
Sudden death in cancer patient on high-dose domperidone. Lancet (1982) 1.60
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol (2005) 1.60
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst (1996) 1.58
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.57
The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol (1990) 1.56
Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer (1994) 1.55
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol (2010) 1.55
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol (2007) 1.54
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.54
Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol (1999) 1.53
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.52
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.52
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol (2010) 1.51
Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol (2011) 1.50
The trials of Dr. Bernard Fisher: a European perspective on an American episode. Control Clin Trials (1997) 1.49
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol (2001) 1.49
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol (2011) 1.49
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.48
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.48
Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 1.48